Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;129(2):201-9.
doi: 10.1007/s11060-016-2168-z. Epub 2016 Jun 9.

Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo

Affiliations

Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo

Jai-Nien Tung et al. J Neurooncol. 2016 Sep.

Abstract

Pentraxin 3 (PTX3) is an inflammatory molecule that is involved in immune responses, inflammation, and cancer. Recent evidence suggests that PTX3 plays a critical role in tumor progression; however, its impact on the biological function of gliomas remains unknown. In the present study, immunohistochemical staining showed that patients with high-grade gliomas exhibited increased expression levels of PTX3 compared to those with low-grade gliomas (P < 0.001). Furthermore, knockdown of PTX3 in GBM8401 cells inhibits proliferation, increases p21 protein levels, and decreases cyclin D1 protein levels, resulting in cell cycle arrest at the G0/G1 phase. In addition, knockdown of PTX3 significantly decreases GBM8401 cell migration and invasion through the downregulation of matrix metalloproteinase-1 and -2 (MMP-1 and MMP-2) expression. In a GBM8401 xenograft animal model, PTX3 knockdown decreases tumor growth in vivo. In conclusion, PTX3 plays an important role in glioma cell proliferation and invasion, and may thus serve as a novel potential therapeutic target in the treatment of gliomas.

Keywords: Gliomas; Invasion; Migration; Pentraxin 3; Proliferation.

PubMed Disclaimer

References

    1. Mol Cancer Ther. 2013 Dec;12(12):2760-71 - PubMed
    1. Expert Rev Mol Diagn. 2014 May;14(4):439-52 - PubMed
    1. Mol Clin Oncol. 2013 Nov;1(6):935-941 - PubMed
    1. Endocrinology. 2008 Mar;149(3):1136-43 - PubMed
    1. Tissue Antigens. 2011 Apr;77(4):271-82 - PubMed

Publication types

MeSH terms